KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Inventory (2016 - 2025)

Historic Inventory for Supernus Pharmaceuticals (SUPN) over the last 14 years, with Q3 2025 value amounting to $79.4 million.

  • Supernus Pharmaceuticals' Inventory rose 2409.78% to $79.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $79.4 million, marking a year-over-year increase of 2409.78%. This contributed to the annual value of $54.3 million for FY2024, which is 2986.13% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Inventory stood at $79.4 million, which was up 2409.78% from $44.0 million recorded in Q2 2025.
  • In the past 5 years, Supernus Pharmaceuticals' Inventory registered a high of $91.5 million during Q4 2022, and its lowest value of $44.0 million during Q2 2025.
  • Its 5-year average for Inventory is $72.6 million, with a median of $77.4 million in 2023.
  • In the last 5 years, Supernus Pharmaceuticals' Inventory skyrocketed by 10569.25% in 2021 and then tumbled by 3540.75% in 2025.
  • Over the past 5 years, Supernus Pharmaceuticals' Inventory (Quarter) stood at $86.0 million in 2021, then grew by 6.49% to $91.5 million in 2022, then dropped by 15.44% to $77.4 million in 2023, then fell by 29.86% to $54.3 million in 2024, then soared by 46.24% to $79.4 million in 2025.
  • Its last three reported values are $79.4 million in Q3 2025, $44.0 million for Q2 2025, and $49.4 million during Q1 2025.